Identification of genetic biomarkers associated with pharmacokinetics and pharmacodynamics of apixaban in Chinese healthy volunteers

References

• January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2019 Jul 9;74(1):104–132.
   PubMed Web of Science ®Google Scholar
• Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011 Sep 15;365(11):981–992.
   PubMed Web of Science ®Google Scholar
• Gong IY, Kim RB. Importance of pharmacokinetic profile and variability as determinants of dose and response to dabigatran, rivaroxaban, and apixaban. Can J Cardiol. 2013 Jul;29(7 Suppl):S24–33.
   PubMed Web of Science ®Google Scholar
• Steinberg BA, Shrader P, Thomas L, et al. Off-label dosing of non-vitamin k antagonist oral anticoagulants and adverse outcomes: the ORBIT-AF II registry. J Am Coll Cardiol. 2016 Dec 20;68(24):2597–2604.
   PubMed Web of Science ®Google Scholar
• Saunders JA, Gustafson WL, Vazquez SR, et al. Real-world assessment of off-label direct oral anticoagulant dosing for venous thromboembolism. J Thromb Thrombolysis. 2019 Oct;48(3):506–510.
   PubMed Web of Science ®Google Scholar
• Rosian AN, Rosian SH, Kiss B, et al. Interindividual variability of apixaban plasma concentrations: influence of clinical and genetic factors in a real-life cohort of atrial fibrillation patients. Genes (Basel). 2020 Apr 17;11(4):438.
   PubMed Web of Science ®Google Scholar
• Wang L, Zhang D, Raghavan N, et al. In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies. Drug Metab Dispos. 2010 Mar;38(3):448–458.
   PubMed Web of Science ®Google Scholar
• Ueshima S, Hira D, Fujii R, et al. Impact of ABCB1, ABCG2, and CYP3A5 polymorphisms on plasma trough concentrations of apixaban in Japanese patients with atrial fibrillation. Pharmacogenet Genomics. 2017 Sep;27(9):329–336.
   PubMed Web of Science ®Google Scholar
• Cullell N, Carrera C, Muino E, et al. Pharmacogenetic studies with oral anticoagulants. Genome-wide association studies in vitamin K antagonist and direct oral anticoagulants. Oncotarget 2018 Jun 26;9(49):29238–29258.
   PubMedGoogle Scholar
• Xie Q, Xiang Q, Mu G, et al. Effect of ABCB1 genotypes on the pharmacokinetics and clinical outcomes of new oral anticoagulants: a systematic review and meta-analysis. Curr Pharm Des. 2018;24(30):3558–3565.
   PubMed Web of Science ®Google Scholar
• Liu Z, Xie Q, Zhang H, et al. Target drug-calibrated anti-xa activity assays and expected peak-trough levels in an asian population: a multicenter study. Am J Cardiovasc Drugs. 2021 Nov;21(6):669–679.
   PubMed Web of Science ®Google Scholar
• Gorlova OY, Xiao X, Tsavachidis S, et al. SNP characteristics and validation success in genome wide association studies. Hum Genet. 2022 Feb;141(2):229–238.
   PubMed Web of Science ®Google Scholar
• Pokorney SD, Chertow GM, Al-Khalidi HR, et al. Apixaban for patients with atrial fibrillation on hemodialysis: a multicenter randomized controlled trial. Circulation. 2022 Dec 6;146(23):1735–1745.
   PubMedGoogle Scholar
• Zhang D, Frost CE, He K, et al. Investigating the enteroenteric recirculation of apixaban, a factor Xa inhibitor: administration of activated charcoal to bile duct-cannulated rats and dogs receiving an intravenous dose and use of drug transporter knockout rats. Drug Metab Dispos. 2013 Apr;41(4):906–915.
   PubMed Web of Science ®Google Scholar
• Ueshima S, Hira D, Kimura Y, et al. Population pharmacokinetics and pharmacogenomics of apixaban in Japanese adult patients with atrial fibrillation. Br J Clin Pharmacol. 2018 Jun;84(6):1301–1312.
   PubMed Web of Science ®Google Scholar
• Gulilat M, Keller D, Linton B, et al. Drug interactions and pharmacogenetic factors contribute to variation in apixaban concentration in atrial fibrillation patients in routine care. J Thromb Thrombolysis. 2020 Feb;49(2):294–303.
   PubMed Web of Science ®Google Scholar
• Dimatteo C, D’Andrea G, Vecchione G, et al. ABCB1 SNP rs4148738 modulation of apixaban interindividual variability. Thromb Res. 2016;Sep;145:24–26.
   PubMed Web of Science ®Google Scholar
• Huppertz A, Grond-Ginsbach C, Dumschat C, et al. Unexpected excessive apixaban exposure: case report of a patient with polymorphisms of multiple apixaban elimination pathways. BMC Pharmacol Toxicol. 2019 Aug 29;20(1):53.
   PubMed Web of Science ®Google Scholar
• Kryukov AV, Sychev DA, Andreev DA, et al. Influence of ABCB1 and CYP3A5 gene polymorphisms on pharmacokinetics of apixaban in patients with atrial fibrillation and acute stroke. Pharmgenomics Pers Med. 2018;11:43–49.
   PubMed Web of Science ®Google Scholar
• Shnayder NA, Petrova MM, Shesternya PA, et al. Using pharmacogenetics of direct oral anticoagulants to predict changes in their pharmacokinetics and the risk of adverse drug reactions. Biomedicines. 2021 Apr 22;9(5):451.
   PubMed Web of Science ®Google Scholar
• Raghavan N, Frost CE, Yu Z, et al. Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab Dispos. 2009 Jan;37(1):74–81.
   PubMed Web of Science ®Google Scholar
• Carlini EJ, Raftogianis RB, Wood TC, et al. Sulfation pharmacogenetics: SULT1A1 and SULT1A2 allele frequencies in Caucasian, Chinese and African-American subjects. Pharmacogenetics. 2001 Feb;11(1):57–68.
   PubMedGoogle Scholar
• Raftogianis RB, Wood TC, Otterness DM, et al. Phenol sulfotransferase pharmacogenetics in humans: association of common SULT1A1 alleles with TS PST phenotype. Biochem Biophys Res Commun. 1997 Oct 9;239(1):298–304.
   PubMed Web of Science ®Google Scholar
• Nagar S, Walther S, Blanchard RL. Sulfotransferase (SULT) 1A1 polymorphic variants *1, *2, and *3 are associated with altered enzymatic activity, cellular phenotype, and protein degradation. Mol Pharmacol. 2006 Jun;69(6):2084–2092.
   PubMed Web of Science ®Google Scholar
• Barrientos T, Frank D, Kuwahara K, et al. Two novel members of the ABLIM protein family, ABLIM-2 and −3, associate with STARS and directly bind F-actin. J Biol Chem. 2007 Mar 16;282(11):8393–8403.
   PubMed Web of Science ®Google Scholar
• Liang ZZ, Zhang YX, Zhu RM, et al. Identification of epigenetic modifications mediating the antagonistic effect of selenium against cadmium-induced breast carcinogenesis. Environ Sci Pollut Res Int. 2022 Mar;29(15):22056–22068.
   PubMed Web of Science ®Google Scholar
• Li X, Han Y, Li D, et al. Identification and validation of a dysregulated miRNA-associated mRNA network in temporal lobe epilepsy. Biomed Res Int. 2021;2021:4118216.
   PubMed Web of Science ®Google Scholar
• Li J, Chen F, Zhang Q, et al. Genome-wide network-assisted association and enrichment study of amyloid imaging phenotype in alzheimer’s disease. Curr Alzheimer Res. 2019;16(13):1163–1174.
   PubMed Web of Science ®Google Scholar
• Freitag-Wolf S, Munz M, Junge O, et al. Sex-specific genetic factors affect the risk of early-onset periodontitis in Europeans. J Clin Periodontol. 2021 Nov;48(11):1404–1413.
   PubMed Web of Science ®Google Scholar
• Cheishvili D, Parashar S, Mahmood N, et al. Identification of an epigenetic signature of osteoporosis in blood DNA of postmenopausal women. J Bone Miner Res. 2018 Nov;33(11):1980–1989.
   PubMed Web of Science ®Google Scholar
• Dhar A, Sadiq F, Anstee QM, et al. Thrombin and factor Xa link the coagulation system with liver fibrosis. BMC Gastroenterol. 2018 May 8;18(1):60.
   PubMedGoogle Scholar
• Alshehri FSM, Whyte CS, Mutch NJ, et al. “Factor” in haemostasis and wound healing. Int J Mol Sci. 2021 Mar 17;22(6):3055.
   PubMed Web of Science ®Google Scholar
• Mitchell JL, Mutch NJ. Let’s cross-link: diverse functions of the promiscuous cellular transglutaminase factor XIII-A. J Thromb Haemost. 2019 Jan;17(1):19–30.
   PubMed Web of Science ®Google Scholar
• Moret A, Zuniga A, Ayala JM, et al. Factor XIII deficiency in two Spanish families with a novel variant in gene F13A1 detected by next-generation sequencing; symptoms and clinical management. J Thromb Thrombolysis. 2020 Oct;50(3):686–688.
   PubMed Web of Science ®Google Scholar
• Xiang H, Wang C, Pan H, et al. Exome-sequencing identifies novel genes associated with recurrent pregnancy loss in a Chinese cohort. Front Genet. 2021;12:746082.
   PubMed Web of Science ®Google Scholar
• Forgerini M, Lucchetta RC, Urbano G, et al. Genetic polymorphisms associated with upper gastrointestinal bleeding: a systematic review. Pharmacogenomics J. 2021 Feb;21(1):20–36.
   PubMed Web of Science ®Google Scholar
• Gemmati D, Vigliano M, Burini F, et al. Coagulation factor XIIIA (F13A1): novel perspectives in treatment and pharmacogenetics. Curr Pharm Des. 2016;22(11):1449–1459.
   PubMed Web of Science ®Google Scholar
• Ansani L, Marchesini J, Pestelli G, et al. F13A1 gene variant (V34L) and residual circulating FXIIIA levels predict short- and long-term mortality in acute myocardial infarction after coronary angioplasty. Int J Mol Sci. 2018 Sep 14;19(9):2766.
   PubMed Web of Science ®Google Scholar
• Dull K, Fazekas F, Factor TD. XIII-A in diseases: role beyond blood coagulation. Int J Mol Sci. 2021 Feb 1;22(3):1459.
   PubMed Web of Science ®Google Scholar
• Berkowitz S, Chapman J, Dori A, et al. Complement and coagulation system crosstalk in synaptic and neural conduction in the central and peripheral nervous systems. Biomedicines. 2021 Dec 20;9(12):1950.
   PubMed Web of Science ®Google Scholar
• Amara U, Flierl MA, Rittirsch D, et al. Molecular intercommunication between the complement and coagulation systems. J Immunol. 2010 Nov 1;185(9):5628–5636.
   PubMed Web of Science ®Google Scholar
• Gouin-Thibault I, Delavenne X, Blanchard A, et al. Interindividual variability in dabigatran and rivaroxaban exposure: contribution of ABCB1 genetic polymorphisms and interaction with clarithromycin. J Thromb Haemost. 2017 Feb;15(2):273–283.
   PubMed Web of Science ®Google Scholar
• Wang Y, Chen M, Chen H, et al. Influence of ABCB1 gene polymorphism on rivaroxaban blood concentration and hemorrhagic events in patients with atrial fibrillation. Front Pharmacol. 2021;12:639854.
   PubMed Web of Science ®Google Scholar
• Parasrampuria DA, Truitt KE. Pharmacokinetics and pharmacodynamics of edoxaban, a non-vitamin K antagonist oral anticoagulant that inhibits clotting factor Xa. Clin Pharmacokinet. 2016 Jun;55(6):641–655.
   PubMed Web of Science ®Google Scholar
• Vandell AG, Lee J, Shi M, et al. An integrated pharmacokinetic/pharmacogenomic analysis of ABCB1 and SLCO1B1 polymorphisms on edoxaban exposure. Pharmacogenomics J. 2018 Jan;18(1):153–159.
   PubMed Web of Science ®Google Scholar
• Nakagawa J, Kinjo T, Aiuchi N, et al. Associations among plasma concentrations of edoxaban and M-4, prothrombin time, and the SLCO1B1*15 haplotype in patients with non-valvular atrial fibrillation. Ther Drug Monit. 2022 Sep;23:10–27.
   Google Scholar